Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 346 AL 360

Microglial metabolic reprogramming in Alzheimer's disease: Pathways, mechanisms, and therapeutic implications

Yang FG, Yang H, Han SW, Wang JT, Gao W, Ye QY, Zhang MM, Yang Y, Li HL.

Ageing Res Rev. 2026 Apr;116:103050. doi: 10.1016/j.arr.2026.103050. Epub 2026 Feb 4.

An Insight into Medicinal Chemistry and SAR Studies of Cholinesterase and BACE-1 Inhibitors for Alzheimer's Disease

Shome A, Jha KT, Chahat, Chawla V, Chawla PA.

CNS Neurol Disord Drug Targets. 2026;25(2):104-129. doi: 10.2174/0118715273315191241002115155.

cGAS-STING signaling in Alzheimer's disease: Microglial mechanisms and therapeutic opportunities

Fazal F, Dar NJ, Ahamad S, Khan S, Bano N, Saha S, Nazir A, Bhat SA.

Mol Aspects Med. 2026 Feb;107:101444. doi: 10.1016/j.mam.2025.101444. Epub 2026 Jan 1.

Receptor tyrosine kinases in Alzheimer's disease: Mechanistic insights and therapeutic implications

Zhao P, Cao Z, Rozpędek-Kamińska W.

Neurochem Int. 2026 Feb;193:106117. doi: 10.1016/j.neuint.2026.106117. Epub 2026 Jan 8.

Evaluation of ASC as a therapeutic target for Alzheimer's disease

Clayton WB, Kulas JA, Liu J, Walia N, Rangel-Barajas C, Johnson T, Zhang J, Huang K, Mesecar AD, Dage JL, Lamb BT, Palkowitz AD, Richardson TI.

Alzheimers Dement. 2026 Jan;22(1):e71104. doi: 10.1002/alz.71104.

Targeting the Nrf2/HO-1 aixs: A therapeutic strategy against regulated cell death in Alzheimer's disease

Wang Z, Feng W, Li X, Yun X, Wu S, Du L, Wang H.

Ageing Res Rev. 2026 Apr;116:103035. doi: 10.1016/j.arr.2026.103035. Epub 2026 Jan 28.

Clinical meaningfulness of anti-amyloid therapies in early Alzheimer's disease: Perspectives from the East and Southeast Asia region

Chen C, Lee JH, Park KH, Hu CJ, Mok V, Senanarong V, Inaba K, Dash A.

Alzheimers Dement. 2026 Feb;22(2):e71230. doi: 10.1002/alz.71230.

Ferroptosis and Alzheimer's disease: a new insight into neurodegeneration

Quan Y, Liu H, Zhang M, Li M, He B, Wang K, Huang X, Zhou S, Han Z, Fan H.

Front Immunol. 2026 Feb 6;17:1701767. doi: 10.3389/fimmu.2026.1701767. eCollection 2026.

The Double-Edged Sword Effect of the Fibrinolytic System in Alzheimer's Disease

Tang M, Liang M, Zhang X, Hong C, Ye L.

Cell Mol Neurobiol. 2026 Feb 27;46(1):66. doi: 10.1007/s10571-026-01699-6.

The evolving landscape of amyloid-targeting therapies in Alzheimer's disease: progress and challenges

Zhang B, Yu X, Zhang X.

Neurol Sci. 2026 Feb 28;47(3):304. doi: 10.1007/s10072-026-08893-w.

Serotonergic psychedelics as epigenetic modulators: A paradigm shift in Alzheimer's disease therapeutics

Gojani EG, Farzin H, Sutherland RJ, Mohajerani MH.

Neurosci Biobehav Rev. 2026 May;184:106619. doi: 10.1016/j.neubiorev.2026.106619. Epub 2026 Feb 28.

PAR-1 in Alzheimer's Disease: Pathophysiological Insights and Mechanistic Perspectives

Neha, Mandal S, Sharma V, Dhindsa J, Aran KR.

Curr Med Sci. 2026 Apr;46(2):297-306. doi: 10.1007/s11596-026-00175-y. Epub 2026 Mar 5.

Decoding the key mechanisms of ferroptosis and inflammation: Emerging therapeutic targets for Alzheimer's disease

Yang Y, Yang F, Yao M, Li L, Li H.

J Alzheimers Dis. 2026 Apr;110(4):1584-1601. doi: 10.1177/13872877261427028. Epub 2026 Mar 6.

Therapeutic Potential of Somatostatin and Its Analogues in Alzheimer's Disease: From Molecular Mechanisms to Preclinical Studies

Liu K, Zhang XY, Wang YT, Wang R, Jin RH, Bing YH.

Mol Neurobiol. 2026 Mar 19;63(1):508. doi: 10.1007/s12035-026-05803-1.

Interplay of oxidative stress and neuroinflammation in alzheimer's: insights into age-driven pathogenesis

Firdous SM, Chakrabortty S, Undale VR, Mallik S, Gouda M.

Inflammopharmacology. 2026 Apr;34(4):2243-2263. doi: 10.1007/s10787-026-02169-7. Epub 2026 Mar 10.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias